• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用液相色谱-串联质谱法测定比卡鲁胺酸代谢物在比格犬血浆中的含量及药代动力学研究。

Determination and pharmacokinetic study of the diacid metabolite of norcantharidin in beagle plasma by use of liquid chromatography-tandem mass spectrometry.

机构信息

College of Pharmaceutical Science, Zhejiang Chinese Medical University, No. 548, Binwen Road, 310053, Hangzhou, China.

出版信息

Anal Bioanal Chem. 2013 Nov;405(28):9273-83. doi: 10.1007/s00216-013-7300-8. Epub 2013 Oct 6.

DOI:10.1007/s00216-013-7300-8
PMID:24096565
Abstract

Because norcantharidin (NCTD) is unstable and subject to ring opening and hydrolysis, the diacid metabolite of norcantharidin (DM-NCTD) is the stable form of NCTD found in normal saline solution. Conversion of NCTD to DM-NCTD is almost 100%, making it possible to determine and investigate the pharmacokinetics of DM-NCTD converted from NCTD. In this paper, a sensitive, simple and selective liquid chromatographic-tandem mass spectrometric method was developed and validated for determination of DM-NCTD in beagle plasma. DM-NCTD was detected in multiple-reaction monitoring (MRM) mode by using the dehydrated ion 169.3 as precursor ion and its product ion 123.1 as the detected ion. Ribavirin was used as internal standard and detected in MRM mode by use of precursor ions, resulting in a product ion transition of m/z 267.1 → 135.1. This method was successfully used for a pharmacokinetic study of DM-NCTD in beagles after intravenous administration of DM-NCTD in normal saline solution at doses of 0.39, 0.78, and 1.6 mg kg(-1). DM-NCTD had dose-dependent kinetics across the dosage range investigated, with enhanced T(1/2α) and AUC(0-12) and apparently decreasing V(d) and CL with increasing dosage. After single-dose administration, T(1/2α) ranged from 0.20 to 0.55 h, AUC(0-12) from 1.81 to 43.6 μg mL(-1) h(-1), V(d) from 228 to 55.9 mL kg(-1), and CL from 220 to 36.5 mL kg(-1) h(-1) (P < 0.01). The results indicated nonlinear pharmacokinetic behavior of DM-NCTD in beagles, suggesting that the risk of DM-NCTD in normal saline solution intoxication may be non-proportionally increased at higher doses.

摘要

由于去甲斑蝥素(NCTD)不稳定,易开环水解,NCTD 的二酸代谢物(DM-NCTD)是生理盐水溶液中 NCTD 的稳定形式。NCTD 转化为 DM-NCTD 的转化率几乎为 100%,这使得可以确定和研究从 NCTD 转化而来的 DM-NCTD 的药代动力学。在本文中,开发并验证了一种灵敏、简单和选择性的液相色谱-串联质谱法,用于测定犬血浆中的 DM-NCTD。DM-NCTD 采用多重反应监测(MRM)模式检测,脱水离子 169.3 作为前体离子,其产物离子 123.1 作为检测离子。利巴韦林作为内标,采用 MRM 模式检测,前体离子产生的产物离子跃迁为 m/z 267.1→135.1。该方法成功地用于在犬中静脉注射生理盐水溶液中 DM-NCTD 剂量为 0.39、0.78 和 1.6 mg kg(-1) 后的 DM-NCTD 药代动力学研究。DM-NCTD 在研究剂量范围内呈剂量依赖性动力学,随着剂量的增加,T(1/2α)和 AUC(0-12)增加,V(d)和 CL 明显减少。单次给药后,T(1/2α)范围为 0.20 至 0.55 h,AUC(0-12)范围为 1.81 至 43.6 μg mL(-1) h(-1),V(d)范围为 228 至 55.9 mL kg(-1),CL 范围为 220 至 36.5 mL kg(-1) h(-1)(P < 0.01)。结果表明,DM-NCTD 在犬中的药代动力学呈非线性,这表明在较高剂量下,DM-NCTD 在生理盐水中中毒的风险可能不成比例增加。

相似文献

1
Determination and pharmacokinetic study of the diacid metabolite of norcantharidin in beagle plasma by use of liquid chromatography-tandem mass spectrometry.采用液相色谱-串联质谱法测定比卡鲁胺酸代谢物在比格犬血浆中的含量及药代动力学研究。
Anal Bioanal Chem. 2013 Nov;405(28):9273-83. doi: 10.1007/s00216-013-7300-8. Epub 2013 Oct 6.
2
Liquid chromatography-tandem mass spectrometry evaluation of the pharmacokinetics of a diacid metabolite of norcantharidin loaded in folic acid-targeted liposomes in mice.叶酸靶向脂质体包裹的去甲斑蝥素二酸代谢产物在小鼠体内药代动力学的液相色谱-串联质谱评价
J Pharm Biomed Anal. 2016 Feb 5;119:76-83. doi: 10.1016/j.jpba.2015.11.017. Epub 2015 Nov 18.
3
Determination and pharmacokinetic study of norcantharidin in human serum by HPLC-MS/MS method.采用HPLC-MS/MS法测定人血清中去甲斑蝥素并进行药代动力学研究。
Biomed Chromatogr. 2008 Jan;22(1):44-9. doi: 10.1002/bmc.892.
4
Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.装载去甲斑蝥素二酸代谢物的叶酸受体靶向脂质体增强了对H22肝癌细胞的体内外抗肿瘤效力。
Int J Nanomedicine. 2016 Apr 4;11:1395-412. doi: 10.2147/IJN.S96862. eCollection 2016.
5
Development and validation of an LC-ESI-MS/MS approach to determine a highly hydrophobic drug, norcantharidin palmitate, and apply to a preliminary pharmacokinetic study in rats.开发并验证一种用于测定高疏水性药物棕榈酸去甲斑蝥素的液相色谱-电喷雾串联质谱法,并将其应用于大鼠的初步药代动力学研究。
Biomed Chromatogr. 2017 Dec;31(12). doi: 10.1002/bmc.4010. Epub 2017 Jun 5.
6
[In vitro and in vivo assesemet of sodium norcantharidin lipid microsphere].去甲斑蝥酸钠脂质微球的体外与体内评价
Yao Xue Xue Bao. 2006 Aug;41(8):784-8.
7
Determination of norcantharidin in mouse tissues by liquid chromatography coupled to tandem mass spectrometry and its tissue distribution study.液相色谱-串联质谱法测定小鼠组织中的去甲斑蝥素及其组织分布研究
Arzneimittelforschung. 2012 Jun;62(6):290-4. doi: 10.1055/s-0032-1308980. Epub 2012 Apr 2.
8
Development of a rapid and sensitive liquid chromatography/tandem mass spectrometry method for the determination of 1,2-[bis(1,2-benzisoselenazolone-3(2H)-ketone)]-ethane (BBSKE), a novel anti-cancer agent in rat plasma.开发一种快速灵敏的液相色谱/串联质谱法,用于测定大鼠血浆中的新型抗癌药物1,2 - [双(1,2 - 苯并异硒唑啉 - 3(2H)-酮)] - 乙烷(BBSKE)。
Biomed Chromatogr. 2008 Oct;22(10):1123-9. doi: 10.1002/bmc.1034.
9
Simultaneous determination of asperosaponin VI and its active metabolite hederagenin in rat plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study.采用正负离子切换电喷雾电离的液相色谱-串联质谱法同时测定大鼠血浆中的asperosaponin VI 及其活性代谢物hederagenin 及其在药代动力学研究中的应用。
J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Nov 15;879(30):3407-14. doi: 10.1016/j.jchromb.2011.09.014. Epub 2011 Sep 13.
10
Determination and pharmacokinetic study of the novel anti-tumor candidate drug DG-7 in rat plasma by liquid chromatography-tandem mass spectrometry.采用液相色谱-串联质谱法测定大鼠血浆中新型抗肿瘤候选药物 DG-7 的浓度及其药代动力学。
J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 1;960:14-8. doi: 10.1016/j.jchromb.2014.04.010. Epub 2014 Apr 13.

引用本文的文献

1
Co-encapsulation of norcantharidin prodrugs and lomitapide in nanoparticles to regulate CCL4 expression by inhibiting Wnt/β-catenin pathway for improved anti-tumor immunotherapy.将去甲斑蝥素前药与洛美他派共包封于纳米颗粒中,通过抑制Wnt/β-连环蛋白通路来调节CCL4表达,以改善抗肿瘤免疫治疗。
J Nanobiotechnology. 2025 May 21;23(1):369. doi: 10.1186/s12951-025-03425-8.
2
Review targeted drug delivery systems for norcantharidin in cancer therapy.综述坎尼汀在癌症治疗中的靶向药物传递系统。
J Nanobiotechnology. 2022 Dec 3;20(1):509. doi: 10.1186/s12951-022-01703-3.
3
Strategies for Solubility and Bioavailability Enhancement and Toxicity Reduction of Norcantharidin.
去甲斑蝥素增溶、生物利用度提高和减毒策略。
Molecules. 2022 Nov 10;27(22):7740. doi: 10.3390/molecules27227740.
4
Effect of norcantharidin on the proliferation, apoptosis, and cell cycle of human mesangial cells.去甲斑蝥素对人系膜细胞增殖、凋亡及细胞周期的影响。
Ren Fail. 2017 Nov;39(1):458-464. doi: 10.1080/0886022X.2017.1308257.
5
Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.装载去甲斑蝥素二酸代谢物的叶酸受体靶向脂质体增强了对H22肝癌细胞的体内外抗肿瘤效力。
Int J Nanomedicine. 2016 Apr 4;11:1395-412. doi: 10.2147/IJN.S96862. eCollection 2016.